Stock Price & Analysis

The S1 support level for DCTH Stock is $11.88 ,The R1 resistant level for DCTH Stock is $15.67.

As of the end of day on 2025-01-23, the price of DCTH Stock was $16.28.

The target price for DCTH Stock according to analyst rating is 21.50, with the highest price target at 22.00 and the lowest at 21.00. Analysts have a Strong Buy rating on DCTH Stock overall.

The market cap of DCTH is $515.7M.

Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

DCTH has a total of 76 employees.